US · Healthcare · Medical Instruments & Supplies
EPS came in at -0.04 against a street estimate of -0.10 — a beat of 60.0%.
Analysts rate AngioDynamics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $20.00.
CONFIDENT AngioDynamics delivered 6.9% revenue growth, strong MedTech momentum, improved adjusted loss and EBITDA, and maintained FY27 guidance despite continued cash use and tariff uncertainty. Q1 FY27 No regional revenue breakdown was provided. Analysts focused on NanoKnife utilization, thrombectomy commercial execution, cash usage, seasonality and margins. Management emphasized healthy adoption trends, continued catalysts and maintained guidance. 2026-10-08…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.04% |
| Point72 Asset Management, L.P. | 7.28% |
| Systematic Financial Management LP | 6.28% |
| Armistice Capital, LLC | 5.23% |
| Royce & Associates, LP | 4.68% |
| Broadfin Holdings LLC | 4.32% |
| Vanguard Capital Management, LLC | 4.03% |
| Weber Capital Management LLC | 3.23% |
| Document | Date |
|---|---|
| Annual report FY2026 HEADLINE NUMBERS • Fiscal year ended May 31, 2026. • AngioDynamics had approximately $436,293,219 of common stock held by non-affiliates as of Novem | 2026-07-14 |
| Results announced · Q1 FY2027 HEADLINE NUMBERS • Fiscal 2026 net sales were $320.2 million, up 9.4% pro forma year over year. • Med Tech sales were $150.0 million, up 18.4%; Med | 2026-07-14 |
| Company announcement · Q4 FY2026 HEADLINE NUMBERS • On April 23, 2026, AngioDynamics filed a patent infringement lawsuit in the United States District Court for the District of Delaw | 2026-04-23 |
| Quarterly report · Q3 FY2026 HEADLINE NUMBERS • Third-quarter fiscal 2026 net sales were $78,423, up from $72,004 in the prior-year quarter, an increase of approximately 8.9%. • | 2026-04-02 |
| Results announced · Q4 FY2026 HEADLINE NUMBERS • Fiscal Q3 2026 net sales were $78.4 million, up 8.9% year over year on a pro forma basis. • Med Tech sales were $37.3 million, up | 2026-04-02 |
| Board / officer change · Q3 FY2026 HEADLINE NUMBERS • AngioDynamics announced transition arrangements related to CEO James C. Clemmer’s planned retirement. • Mr. Clemmer will remain P | 2026-02-03 |
| Quarterly report · Q2 FY2026 HEADLINE NUMBERS • For the three months ended November 30, 2025, net sales were $79,433,000, up from $72,845,000, an increase of approximately 9%. • | 2026-01-06 |
| Quarterly report · Q1 FY2026 HEADLINE NUMBERS • Fiscal Q1 2026 net sales were $75.711 million, up from $67.491 million in the prior-year quarter, an increase of approximately 12. | 2025-10-02 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AngioDynamics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.